Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 157

1.

Liver-Type Glutaminase GLS2 Is a Druggable Metabolic Node in Luminal-Subtype Breast Cancer.

Lukey MJ, Cluntun AA, Katt WP, Lin MJ, Druso JE, Ramachandran S, Erickson JW, Le HH, Wang ZE, Blank B, Greene KS, Cerione RA.

Cell Rep. 2019 Oct 1;29(1):76-88.e7. doi: 10.1016/j.celrep.2019.08.076.

2.

Structures of the Rhodopsin-Transducin Complex: Insights into G-Protein Activation.

Gao Y, Hu H, Ramachandran S, Erickson JW, Cerione RA, Skiniotis G.

Mol Cell. 2019 Aug 22;75(4):781-790.e3. doi: 10.1016/j.molcel.2019.06.007. Epub 2019 Jul 9.

PMID:
31300275
3.

Effect of heritable symbionts on maternally-derived embryo transcripts.

Mateos M, Silva NO, Ramirez P, Higareda-Alvear VM, Aramayo R, Erickson JW.

Sci Rep. 2019 Jun 20;9(1):8847. doi: 10.1038/s41598-019-45371-0.

4.

Reconstitution of the Rhodopsin-Transducin Complex into Lipid Nanodiscs.

Gao Y, Erickson JW, Cerione RA, Ramachandran S.

Methods Mol Biol. 2019;2009:317-324. doi: 10.1007/978-1-4939-9532-5_24.

PMID:
31152414
5.

Purification of the Rhodopsin-Transducin Complex for Structural Studies.

Gao Y, Erickson JW, Cerione RA, Ramachandran S.

Methods Mol Biol. 2019;2009:307-315. doi: 10.1007/978-1-4939-9532-5_23.

PMID:
31152413
6.

Gain-of-function screen of α-transducin identifies an essential phenylalanine residue necessary for full effector activation.

Milano SK, Wang C, Erickson JW, Cerione RA, Ramachandran S.

J Biol Chem. 2018 Nov 16;293(46):17941-17952. doi: 10.1074/jbc.RA118.003746. Epub 2018 Sep 28.

PMID:
30266806
7.

Isolation and structure-function characterization of a signaling-active rhodopsin-G protein complex.

Gao Y, Westfield G, Erickson JW, Cerione RA, Skiniotis G, Ramachandran S.

J Biol Chem. 2017 Aug 25;292(34):14280-14289. doi: 10.1074/jbc.M117.797100. Epub 2017 Jun 27.

8.

Fluorination at the 4 position alters the substrate behavior of L-glutamine and L-glutamate: Implications for positron emission tomography of neoplasias.

Jeitner TM, Kristoferson E, Azcona JA, Pinto JT, Stalnecker C, Erickson JW, Kung HF, Li J, Ploessl K, Cooper AJL.

J Fluor Chem. 2016 Dec;192(A):58-67. doi: 10.1016/j.jfluchem.2016.10.008. Epub 2016 Oct 20.

9.

Veterans treatment courts: A case study of their efficacy for Veterans' needs.

Erickson JW Jr.

Int J Law Psychiatry. 2016 Nov - Dec;49(Pt B):221-225. doi: 10.1016/j.ijlp.2016.10.009. Epub 2016 Oct 27.

PMID:
28340906
10.

Conformational changes in the activation loop of mitochondrial glutaminase C: A direct fluorescence readout that distinguishes the binding of allosteric inhibitors from activators.

Stalnecker CA, Erickson JW, Cerione RA.

J Biol Chem. 2017 Apr 14;292(15):6095-6107. doi: 10.1074/jbc.M116.758219. Epub 2017 Feb 14.

11.

Mechanistic Basis of Glutaminase Activation: A KEY ENZYME THAT PROMOTES GLUTAMINE METABOLISM IN CANCER CELLS.

Li Y, Erickson JW, Stalnecker CA, Katt WP, Huang Q, Cerione RA, Ramachandran S.

J Biol Chem. 2016 Sep 30;291(40):20900-20910. Epub 2016 Aug 19.

12.

The oncogenic transcription factor c-Jun regulates glutaminase expression and sensitizes cells to glutaminase-targeted therapy.

Lukey MJ, Greene KS, Erickson JW, Wilson KF, Cerione RA.

Nat Commun. 2016 Apr 18;7:11321. doi: 10.1038/ncomms11321.

13.

Primary Sex Determination in Drosophila melanogaster Does Not Rely on the Male-Specific Lethal Complex.

Erickson JW.

Genetics. 2016 Feb;202(2):541-9. doi: 10.1534/genetics.115.182931. Epub 2015 Nov 27.

14.

Mechanism by which a recently discovered allosteric inhibitor blocks glutamine metabolism in transformed cells.

Stalnecker CA, Ulrich SM, Li Y, Ramachandran S, McBrayer MK, DeBerardinis RJ, Cerione RA, Erickson JW.

Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):394-9. doi: 10.1073/pnas.1414056112. Epub 2014 Dec 29.

15.

Prenylation and membrane localization of Cdc42 are essential for activation by DOCK7.

Zhou Y, Johnson JL, Cerione RA, Erickson JW.

Biochemistry. 2013 Jun 25;52(25):4354-63. doi: 10.1021/bi301688g. Epub 2013 Jun 14.

16.

Rho GTPases and their roles in cancer metabolism.

Wilson KF, Erickson JW, Antonyak MA, Cerione RA.

Trends Mol Med. 2013 Feb;19(2):74-82. doi: 10.1016/j.molmed.2012.10.011. Epub 2012 Dec 5. Review.

17.

Dibenzophenanthridines as inhibitors of glutaminase C and cancer cell proliferation.

Katt WP, Ramachandran S, Erickson JW, Cerione RA.

Mol Cancer Ther. 2012 Jun;11(6):1269-78. doi: 10.1158/1535-7163.MCT-11-0942. Epub 2012 Apr 11.

18.

New active HIV-1 protease inhibitors derived from 3-hexanol: conformation study of the free inhibitors in crystalline state and in complex with the enzyme.

Ziółkowska NE, Bujacz A, Randad RS, Erickson JW, Skálová T, Hašek J, Bujacz G.

Chem Biol Drug Des. 2012 May;79(5):798-809. doi: 10.1111/j.1747-0285.2012.01328.x. Epub 2012 Mar 7.

PMID:
22296826
19.

C-terminal di-arginine motif of Cdc42 protein is essential for binding to phosphatidylinositol 4,5-bisphosphate-containing membranes and inducing cellular transformation.

Johnson JL, Erickson JW, Cerione RA.

J Biol Chem. 2012 Feb 17;287(8):5764-74. doi: 10.1074/jbc.M111.336487. Epub 2012 Jan 3.

20.

A quantitative fluorometric approach for measuring the interaction of RhoGDI with membranes and Rho GTPases.

Johnson J, Cerione RA, Erickson JW.

Methods Mol Biol. 2012;827:107-19. doi: 10.1007/978-1-61779-442-1_8.

21.

Glutaminase: a hot spot for regulation of cancer cell metabolism?

Erickson JW, Cerione RA.

Oncotarget. 2010 Dec;1(8):734-40. Review.

22.

A minimal Rac activation domain in the unconventional guanine nucleotide exchange factor Dock180.

Wu X, Ramachandran S, Lin MC, Cerione RA, Erickson JW.

Biochemistry. 2011 Feb 15;50(6):1070-80. doi: 10.1021/bi100971y. Epub 2011 Jan 20.

23.

Targeting mitochondrial glutaminase activity inhibits oncogenic transformation.

Wang JB, Erickson JW, Fuji R, Ramachandran S, Gao P, Dinavahi R, Wilson KF, Ambrosio AL, Dias SM, Dang CV, Cerione RA.

Cancer Cell. 2010 Sep 14;18(3):207-19. doi: 10.1016/j.ccr.2010.08.009. Erratum in: Cancer Cell. 2010 Oct 19;18(4):397.

24.

Sex determination in Drosophila: The view from the top.

Salz HK, Erickson JW.

Fly (Austin). 2010 Jan-Mar;4(1):60-70. Epub 2010 Jan 21. Review.

25.

New insights into how the Rho guanine nucleotide dissociation inhibitor regulates the interaction of Cdc42 with membranes.

Johnson JL, Erickson JW, Cerione RA.

J Biol Chem. 2009 Aug 28;284(35):23860-71. doi: 10.1074/jbc.M109.031815. Epub 2009 Jul 6.

26.

A shared enhancer controls a temporal switch between promoters during Drosophila primary sex determination.

González AN, Lu H, Erickson JW.

Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18436-41. doi: 10.1073/pnas.0805993105. Epub 2008 Nov 14.

27.

Maternal Groucho and bHLH repressors amplify the dose-sensitive X chromosome signal in Drosophila sex determination.

Lu H, Kozhina E, Mahadevaraju S, Yang D, Avila FW, Erickson JW.

Dev Biol. 2008 Nov 15;323(2):248-60. doi: 10.1016/j.ydbio.2008.08.012. Epub 2008 Aug 22.

28.

A new tool for G protein analysis.

Erickson JW, Cerione RA.

ACS Chem Biol. 2008 Jan 18;3(1):24-6. doi: 10.1021/cb700239d.

PMID:
18205289
29.
30.
31.

Drosophila BAP60 is an essential component of the Brahma complex, required for gene activation and repression.

Möller A, Avila FW, Erickson JW, Jäckle H.

J Mol Biol. 2005 Sep 16;352(2):329-37.

PMID:
16083904
32.
33.

Drosophila KAP interacts with the kinesin II motor subunit KLP64D to assemble chordotonal sensory cilia, but not sperm tails.

Sarpal R, Todi SV, Sivan-Loukianova E, Shirolikar S, Subramanian N, Raff EC, Erickson JW, Ray K, Eberl DF.

Curr Biol. 2003 Sep 30;13(19):1687-96.

34.

Structures of Ser205 mutant plasmepsin II from Plasmodium falciparum at 1.8 A in complex with the inhibitors rs367 and rs370.

Asojo OA, Afonina E, Gulnik SV, Yu B, Erickson JW, Randad R, Medjahed D, Silva AM.

Acta Crystallogr D Biol Crystallogr. 2002 Dec;58(Pt 12):2001-8. Epub 2002 Nov 23.

PMID:
12454457
35.

Utility of (His)6 tag for purification and refolding of proplasmepsin-2 and mutants with altered activation properties.

Gulnik SV, Afonina EI, Gustchina E, Yu B, Silva AM, Kim Y, Erickson JW.

Protein Expr Purif. 2002 Apr;24(3):412-9.

PMID:
11922757
36.

A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site.

Yoshimura K, Kato R, Kavlick MF, Nguyen A, Maroun V, Maeda K, Hussain KA, Ghosh AK, Gulnik SV, Erickson JW, Mitsuya H.

J Virol. 2002 Feb;76(3):1349-58.

37.

Sex and the neighboring cell.

Erickson JW.

Dev Cell. 2001 Aug;1(2):156-8. Review.

38.

Multiple roles for Cdc42 in cell regulation.

Erickson JW, Cerione RA.

Curr Opin Cell Biol. 2001 Apr;13(2):153-7. Review.

PMID:
11248548
39.
40.
41.

Protease inhibitors: resistance, cross-resistance, fitness and the choice of initial and salvage therapies.

Erickson JW, Gulnik SV, Markowitz M.

AIDS. 1999;13 Suppl A:S189-204. Review. No abstract available.

PMID:
10885776
42.

The gamma-subunit of the coatomer complex binds Cdc42 to mediate transformation.

Wu WJ, Erickson JW, Lin R, Cerione RA.

Nature. 2000 Jun 15;405(6788):800-4.

PMID:
10866202
43.

A novel putative transcription factor protein MYT2 that preferentially binds supercoiled DNA and induces DNA synthesis in quiescent cells.

Shao W, Lee AY, Gulnik S, Gustchina E, Liu YL, Kung H, Erickson JW.

FEBS Lett. 2000 May 19;473(3):363-9.

44.

The Drosophila melanogaster sex determination gene sisA is required in yolk nuclei for midgut formation.

Walker JJ, Lee KK, Desai RN, Erickson JW.

Genetics. 2000 May;155(1):191-202.

45.

HIV protease: enzyme function and drug resistance.

Gulnik S, Erickson JW, Xie D.

Vitam Horm. 2000;58:213-56. Review.

PMID:
10668400
46.

Nonpeptidic HIV protease inhibitors possessing excellent antiviral activities and therapeutic indices. PD 178390: a lead HIV protease inhibitor.

Prasad JV, Boyer FE, Domagala JM, Ellsworth EL, Gajda C, Hamilton HW, Hagen SE, Markoski LJ, Steinbaugh BA, Tait BD, Humblet C, Lunney EA, Pavlovsky A, Rubin JR, Ferguson D, Graham N, Holler T, Hupe D, Nouhan C, Tummino PJ, Urumov A, Zeikus E, Zeikus G, Gracheck SJ, Erickson JW, et al.

Bioorg Med Chem. 1999 Dec;7(12):2775-800.

PMID:
10658583
47.

Real-time measurements of dark substrate catalysis.

Xie D, Suvorov L, Erickson JW, Gulnik AS.

Protein Sci. 1999 Nov;8(11):2460-4.

48.

Drug resistance mutations can effect dimer stability of HIV-1 protease at neutral pH.

Xie D, Gulnik S, Gustchina E, Yu B, Shao W, Qoronfleh W, Nathan A, Erickson JW.

Protein Sci. 1999 Aug;8(8):1702-7.

49.
50.

Kinetics of Cdc42 membrane extraction by Rho-GDI monitored by real-time fluorescence resonance energy transfer.

Nomanbhoy TK, Erickson JW, Cerione RA.

Biochemistry. 1999 Feb 9;38(6):1744-50.

PMID:
10026253

Supplemental Content

Loading ...
Support Center